# US 11,298,364 B2 · Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,364 B2
- Document ID: US11298364B2
- Status: Granted
- Kind: B2
- Application number: 15/755,719
- Filed: 2016-08-30
- Published: 2018-11-29
- Granted: 2022-04-12
- Earliest claimed: 2015-08-31
- Assignees: The University of Adelaide
- Applicants: The University of Adelaide
- Inventors: Sarah Vreugde; Peter John Wormald
- Web page: https://patentgrep.com/patent/US11298364B2

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods and products for reducing the viability of microorganisms, and to methods and products for preventing and/or treating microorganism infections. Certain embodiments of the present disclosure provide a method for reducing viability of a microorganism. The method comprises exposing the microorganism to an effective amount of an iron chelator and subsequently exposing the microorganism to an effective amount of a non-iron porphyrin, thereby reducing the viability of the microorganism.

## Claims

### Claim 1

A method of preventing and/or treating a microorganism infection in a subject, the method comprising administering to the subject an effective amount of an iron chelator and subsequently administering to the subject an effective amount of a non-iron porphyrin, thereby preventing and/or treating the microorganism infection.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the iron chelator comprises deferiprone.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the method comprises exposing microorganisms associated with the infection to 20 mM or less deferiprone.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the non-iron porphyrin comprises a non-iron metalloprotoporphyrin.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the non-iron porphyrin comprises a gallium protoporphyrin.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the method comprises exposing microorganisms associated with the infection to 200 μg/ml or less of the gallium protoporphyrin.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method comprises administering the non-iron porphyrin to the subject 2 hours or greater after administering the iron chelator to the subject.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the microorganism infection comprises a bacterial infection.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the administering comprises topical administration of the iron chelator and/or the non-iron porphyrin to the site of bacterial infection.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the microorganism infection comprises an infection with a small colony variant of a bacterium, or an antibiotic resistant variant of a bacterium.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the microorganism infection comprises an infection associated with a bacterial biofilm.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the microorganism infection comprises rhinosinusitis.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the microorganism infection comprises an infected wound, a chronic wound, a diabetic wound, a diabetic ulcer, a post-surgery infected wound, an infected wound following abdominal surgery, an implant infection, or a burn injury.

### Claim 14

A hydrogel composition for the prevention and/or treatment of a bacterial infection in a subject comprising an iron chelator and a non-iron porphyrin, wherein the composition provides an immediate or sustained release of the iron chelator and a delayed release of the non-iron porphyrin.

### Claim 15 (depends on 14)

The hydrogel composition according to claim 14, wherein the iron chelator comprises deferiprone.

### Claim 16 (depends on 14)

The hydrogel composition according to claim 14, wherein the non-iron porphyrin comprises a gallium protoporphyrin.

### Claim 17

A method for reducing viability of a microorganism, the method comprising exposing the microorganism to an effective amount of an iron chelator and subsequently exposing the microorganism to an effective amount of a non-iron porphyrin, thereby reducing the viability of the microorganism.